FOLD: Amicus Therapeutics Company Short-Term Debt

Symbol and logo of brand Amicus Therapeutics (FOLD)

Short-term debt of up to one year on the GURU.Markets chart is supported by a stable staff of R&D experts retained through stock options. Amicus Therapeutics (FOLD) generates revenue through the supply of high-cost drugs for patients with Pompe and Fabry diseases via insurance funds. The value of 0.00 is established as the baseline, which, coupled with expanding Galafold sales and a strong pipeline, is driving the company toward net profit.

FOLD (Amicus Therapeutics Inc) Company Short-Term Debts history from 07/04/2022 to 05/09/2026

FOLD (Amicus Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Amicus Therapeutics, Inc.|FOLD - Fair Value Consensus
- market capitalization information:
Market Value Amicus Therapeutics, Inc.|FOLD - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Amicus Therapeutics|FOLD - Book Capitalization|Market Cap to Net Assets Ratio amicusrx.com|FOLD - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Amicus Therapeutics|FOLD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Amicus Therapeutics|FOLD - Company Cumulative Debt|Debt to Book Value Amicus Therapeutics, Inc.|FOLD - Amount of Long-Term Liabilities|Company Short-Term Debts Amicus Therapeutics|Quick Ratio amicusrx.com
- net income and valuation multiples indicators:
FOLD - Company Net Income
Basic company analysis:Amicus Therapeutics, Inc. - FOLD
Mass-produced product of Amicus Corp

An investment audit of Amicus Therapeutics (FOLD) requires an analysis of liabilities maturing within one year, which measure current liquidity and the risk of capital shortages. Monitoring the short-term debt portfolio on GURU.Markets allows for a comparison of the financial burden against the high stability of revenue from rare disease therapies, turning this indicator into a marker of business resilience in the face of debt payments.

Who Amicus Therapeutics competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|89bio, Inc. - Company Short-Term Debts|Short-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Current Liabilities|MDXG: Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|Company Short-Term Debts Matinas BioPharma Holdings, Inc. MTNB|SPRB - Company Short-Term Debt|Galecto Inc (GLTO) - Company Current Liabilities|CTCX: Company Short-Term Debts|LUMO - Short-Term Debt Volume|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Current Liabilities radiuspharm.com (RDUS)